GlassScriptPhysician profile
Deepak K Amin
NPI 1659372829
$29,204.10
in general payments reported to CMS, 2019-2025
55 companies · $4,492 in 2025
The $4,492 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,300 · 2020: $2,280 · 2021: $4,806 · 2022: $3,660 · 2023: $5,562 · 2024: $5,104 · 2025: $4,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $27.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,130.61 |
| Education | $27.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,496.04 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $3,892.60 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $3,699.13 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $3,427.69 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Novo Nordisk INC | $2,088.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,041.67 | 2019-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $905.61 | 2019-2024 | Jardiance, Mounjaro |
| Abbvie INC. | $807.07 | 2021-2024 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $725.51 | 2021-2025 | |
| Allergan, INC. | $698.47 | 2019-2020 | |
| Exact Sciences Corporation | $641.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $573.73 | 2020-2025 | |
| Intra-Sana Laboratories | $537.68 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Abiomed | $496.58 | 2021-2025 | Impella |
| Medtronic Vascular, INC. | $459.76 | 2019-2020 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $373.97 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $351.54 | 2019-2025 | Verquvo, Dificid |
| Ironwood Pharmaceuticals, INC | $344.30 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.65 | 2019-2023 | Trulance |
| Amarin Pharma, INC. | $268.65 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $259.61 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $253.73 | 2024-2025 | Zoryve |
| Braeburn INC. | $227.75 | 2023-2025 | Brixadi |
| Medtronic, INC. | $164.83 | 2023 | Hawkone |
| Stryker Corporation | $158.79 | 2021-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Corcept Therapeutics | $155.79 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $149.32 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.23 | 2025 | Caplyta |
| Shockwave Medical, INC | $136.65 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $136.00 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $133.55 | 2023-2025 | Rexulti |
| Inari Medical, INC. | $132.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Intuity Medical INC | $111.31 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Sunovion Pharmaceuticals INC. | $89.86 | 2019 | |
| Xeris Pharmaceuticals, INC. | $82.33 | 2025 | Gvoke Hypopen, Recorlev |
| Azurity Pharmaceuticals, INC. | $77.47 | 2023-2024 | Horizant, Horizant |
| Akorn, INC. | $75.96 | 2020 | |
| Indivior INC. | $70.49 | 2019-2022 | |
| Astellas Pharma US INC | $47.75 | 2023-2024 | Veozah |
| Biogen, INC. | $40.41 | 2021 | |
| Scilex Pharmaceuticals INC. | $38.65 | 2019 | |
| Acadia Pharmaceuticals INC | $31.91 | 2022-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $31.60 | 2022 | |
| Sun Pharmaceutical Industries INC. | $27.55 | 2020-2021 | |
| Horizon Therapeutics Plc | $25.28 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2019 | |
| Hikma Pharmaceuticals USA | $14.93 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.93 | 2021 | |
| Lundbeck LLC | $14.76 | 2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $14.62 | 2025 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $13.16 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.66 | 2022 | |
| Alkermes, INC. | $12.32 | 2021 | |
| Mannkind Corporation | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.